SLU Researcher Finds Help for Alzheimer's-Associated Agitation with New FDA-Approved Treatment
ST. LOUIS – A Saint Louis University researcher was instrumental in developing the first and only Food and Drug Administration (FDA) approved treatment for agitation associated with Alzheimer’s dementia.
In a paper published in JAMA Neurology, senior author and the inaugural Henry & Amelia Nasrallah Endowed Professor and Director of Geriatric Psychiatry at Saint Louis University George T. Grossberg, M.D., and colleagues shared the results of a national clinical trial. They discovered that REXULTI, also called brexpiprazole, significantly reduced agitation in patients with Alzheimer’s disease and was well tolerated with few side effects.
George Grossberg, M.D. Photo by Sarah Conroy.
Earlier this year, brexpiprazole became the first FDA-approved treatment of agitation-associated Alzheimer’s dementia.
Of the 6.7 million people 65 and older in the US with Alzheimer’s dementia, multiple studies show that about half or more develop agitation.
Agitation associated with Alzheimer’s dementia may include activities like restlessness or more aggressive behavior, like screaming, destroying objects or fighting. Frequent and severe behavioral symptoms can be extremely distressing to the person with Alzheimer’s disease, as well as their families and caregivers.
Antipsychotic drugs are commonly prescribed “off-label” to treat symptoms like aggression and agitation. While these antipsychotics seem to show a modest benefit in treating aggression in the short term, they have adverse effects and other health risks that limit their use over more extended periods.
“When patients with Alzheimer’s dementia develop agitation symptoms, they can become increasingly difficult to manage,” said Grossberg, who is also director of geriatric psychiatry at SLU. “I’m encouraged by the findings of this study which show that brexpiprazole is an effective and well-tolerated medication that can treat the often-debilitating symptoms of agitation associated with dementia due to Alzheimer’s disease.”
In the multicenter Phase 3 clinical trial, researchers evaluated the efficacy and safety of brexpiprazole, a medication used for the treatment of major depressive disorder and schizophrenia, for patients with agitation associated with Alzheimer’s.
The clinical trial was a 12-week, double-blind, placebo-controlled, fixed-dose, parallel-arm trial that enrolled 345 participants at 123 clinical trial sites in Europe and the United States.
Investigators enrolled participants between the ages of 55 to 90 with a diagnosis of probable Alzheimer’s disease and clinically significant symptoms of agitation who lived in a care facility or community-based setting.
Participants were randomly assigned to receive the study drug or a placebo. To participate in the clinical trial, participants had to be stable and have a caregiver who could comply with the study procedures.
“It can be extremely challenging to care for patients with Alzheimer’s disease,” said Grossberg. “Having new medications to help patients who are suffering will enormously benefit patients, healthcare providers, and those caring for their loved ones.”
The clinical trial was supported by Otsuka Pharmaceutical Development & Commercialization and H. Lundbeck.
For more information about the trial, visit ClinicalTrials.gov. The study’s Clinical Trials Identifier is NCT03548584.
Latest Newslink
- A Camp Friendship that Stirred Up Lifelong BondsIn the summer of 2005, Mary Kate Keenoy (Chaifetz Grad '22) and Genevieve Willman met at SLU's Gardens to Tables culinary camp. What started as a shared interest in cooking grew into a lasting friendship that has endured for two decades.
- Bruce Bacon, M.D.: 1949-2025Bruce Bacon, M.D., professor emeritus of internal medicine, died Sunday, July 6, 2025. He was 75. Bacon was known globally for his expertise in all aspects of clinical hepatology, specifically hemochromatosis, viral hepatitis, chronic liver disease / general hepatology, and liver transplant. Bacon was also a member of the research team that discovered the gene for hemochromatosis, HFE, in 1996.
- SLU Launches William L. Clay, Sr. Institute of Civic Engagement and Economic JusticeThe Clay Institute will provide immersive learning experiences and hands-on training that address the social and economic challenges facing the St. Louis region and the nation. Institute programming will be available to all students with an interest in civic engagement and democratic participation.
- SLU Research Explores Depression's Ripple Effect on DiabetesA study conducted by researchers at Saint Louis University found that patients with depression were more likely to have uncontrolled diabetes over time and that depression contributes to a heightened economic burden to diabetes management.
- SLU/YouGov Poll: Statewide Cell Phone Ban for Missouri Schools Popular with VotersGovernor Mike Kehoe has signed Senate Bill 68 into law, enacting a statewide ban on the use of personal electronic devices, including cell phones, tablets, and smartwatches, throughout the school day in Missouri public and public charter schools.
- SLU Vaccine Center Will Enroll Healthy Volunteers in Yellow Fever Vaccine Clinical TrialSaint Louis University's Center for Vaccine Development will enroll up to 70 adult volunteers in a clinical trial to study the safety elicited by a new investigational vaccine for yellow fever, a potentially deadly disease that is spread by mosquitoes. The research is funded by Sanofi Pasteur.
